Genentech announced this week that the FDA has approved an update to its reference rituximab’s (Rituxan) label.
Genentech announced this week that the FDA has approved an update to its reference rituximab’s (Rituxan) label.
In addition to previously being approved for the treatment of non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis (GPA), and microscopic polyangiitis (MPA), the label for reference rituximab will now include information for follow-up treatment in adult patients with GPA and MPA who have achieved disease control with induction treatment.
“As part of our commitment to support people living with rare diseases, we are pleased to provide updated prescribing information for Rituxan to help physicians make more informed decisions about therapeutic options for patients who have achieved disease control with induction treatment,” said Sandra Horning, MD, chief medical officer and head of Global Product Development at Genentech, in a statement.
The label update was based on data from the French Vasculitis Study Group which showed that rituximab plus glucocorticoids resulted in fewer major relapses by month 28 compared with azathioprine treatment. Further, the safety profile was consistent with that previously observed in this patient population. The approval makes the combination treatment the only FDA-approved therapy for these rare blood vessel disorders.
The expanded indications come soon after the FDA’s Oncologic Drug Advisory Committee (ODAC) held a meeting to discuss the Biologics License Application for a proposed rituximab biosimilar, CT-P10, developed by Celltrion and referencing Rituxan.
The committee heard data presented by various speakers that found that, although there were minor differences in clinically active compounds, the totality of the evidence suggested that the proposed biosimilar is highly similar to the reference product.
In a vote on whether the totality of the evidence supported the licensure of CT-P10 as a biosimilar to Rituxan, all 16 committee members voted yes. The product will now be considered for licensure by the FDA, and, if approved, CT-P10 would be the first rituximab biosimilar available in the United States, providing competition to the previously unchallenged Rituxan. Celltrion, notably, is seeking approval for oncology indications only for its biosimilar due to the patent landscape for rituximab.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.